Puma Biotechnology, Inc.

Puma Biotechnology, Inc. company information, Employees & Contact Information

At Puma Biotechnology, our focus is on bringing innovative therapies to patients to enhance cancer care. We are thankful to be part of the HER2+ breast cancer community and are passionate about evaluating options that may benefit patients across the breast cancer therapy spectrum.

Company Details

Employees
249
Founded
-
Address
10880 Wilshire Blvd, Los Angeles,ca 90024,united States
Phone
310-443-4150
Email
in****@****ogy.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Manager jobs.
HQ
Los Angeles, CA
Looking for a particular Puma Biotechnology, Inc. employee's phone or email?

Puma Biotechnology, Inc. Questions

News

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results - Yahoo Finance

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Yahoo Finance

Biotech Leader Puma's CEO Alan Auerbach to Share Company Vision at H.C. Wainwright Global Conference - Stock Titan

Biotech Leader Puma's CEO Alan Auerbach to Share Company Vision at H.C. Wainwright Global Conference Stock Titan

Puma Biotechnology Reports Second Quarter Financial Results - Yahoo Finance

Puma Biotechnology Reports Second Quarter Financial Results Yahoo Finance

Study Assessing Alisertib Monotherapy in Extensive-Stage SCLC Begins - Targeted Oncology

Study Assessing Alisertib Monotherapy in Extensive-Stage SCLC Begins Targeted Oncology

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer - ScienceDirect.com

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer ScienceDirect.com

Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting - Business Wire

Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting Business Wire

Earnings call transcript: Puma Biotechnology beats Q2 2025 earnings forecast - Investing.com

Earnings call transcript: Puma Biotechnology beats Q2 2025 earnings forecast Investing.com

FDA Awards Orphan Drug Designation to Alisertib in ES-SCLC - OncLive

FDA Awards Orphan Drug Designation to Alisertib in ES-SCLC OncLive

Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022 - Business Wire

Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022 Business Wire

Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer - OncLive

Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer OncLive

Earnings call transcript: Puma Biotech Q1 2025 results miss forecasts - Investing.com

Earnings call transcript: Puma Biotech Q1 2025 results miss forecasts Investing.com

Puma Biotechnology Reports Second Quarter Financial Results - Stock Titan

Puma Biotechnology Reports Second Quarter Financial Results Stock Titan

Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS - Business Wire

Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS Business Wire

Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI - Business Wire

Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI Business Wire

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone - PharmiWeb.com

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone PharmiWeb.com

Antitumour activity of neratinib in patients with HER2 -mutant advanced biliary tract cancers - Nature

Antitumour activity of neratinib in patients with HER2 -mutant advanced biliary tract cancers Nature

Puma Biotechnology To Present At UBS Global Conference; Webcast At 2:30 PM ET - RTTNews

Puma Biotechnology To Present At UBS Global Conference; Webcast At 2:30 PM ET RTTNews

Top Puma Biotechnology, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant